Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.   

Example of fractional flow reserve (FFR) calculated using AI and assessment of the plaque in the vessel on a CT scan of the coronaries. This new type of FFR-CT was shown as a work-in-progress by the vendor Elucid. It was shown for the first time at AHA 2022.

PHOTO GALLERY: AHA 2022

A photo essay from the American Heart Association (AHA) 2022 Scientific Sessions Nov. 5-7 in Chicago.

Early catheter ablation superior to medication when treating ventricular tachycardia storm

VT storm is associated with a heightened risk of death or significant complications. Early catheter ablation, it seems, is the most effective treatment option for this potentially fatal condition. 

OAC use among older AFib patients is on the rise

However, researchers noted, there is still considerable room for improvement.

Thumbnail

FDA warns 7 companies for illegally selling dietary supplements that claim to treat CVD

The companies were given 15 days to provide an adequate response to the FDA's warning. The agency said its next step could include legal action. 

Tracking the health benefits of influenza vaccines: ‘If you have heart failure, you should get your flu shot’

The new analysis focused on data from more than 5,000 heart failure patients throughout Asia, the Middle East and Africa.

Elon Musk and Eli Lilly: How a fake tweet caused chaos and reignited the debate over insulin prices

Updated Twitter policies have helped online pranksters cause mischief in recent days, including one specific user who impersonated Eli Lilly and Company and posted that insulin was now free. Lilly's CEO has now commented on the fake tweet read 'round the world—and what it could mean for the company going forward. 

New data from the Phase 3 RAPID clinical trial of etripamil, an investigational calcium channel blocker nasal spray, showed positive results in converting paroxysmal supraventricular tachycardia (PSVT) to normal sinus rhythm in the at-home setting. The presentation was featured during a late-breaking clinical trials session at the American Heart Association (AHA) 2022 Scientific Sessions. #AHA22

Etripamil nasal spray meets primary endpoint of terminating paroxysmal supraventricular tachycardia 

The drug allows patients to take control over their condition with self administration and the therapy and may help lower healthcare costs and resource utilization by keeping these patients out of emergency rooms. 

Jason Andrade, MD, FRCPC, FHRS, director of electrophysiology, Vancouver General Hospital, clinical associate professor, University of British Columbia, and principal investigator for the PROGRESSIVE AF trial, explains how cryoablation can be used as a front-line treatment for atrial fibrillation (AFib). He presented this late-breaking trial at the American Heart Association (AHA) 2022 meeting, which showed the therapy can be used instead of trying drug therapy first. #AHA22 #EPeeps

VIDEO: Cryoablation can be used as frontline therapy before drugs: PROGRESSIVE AF trial

Jason Andrade, MD, director of electrophysiology, Vancouver General Hospital, and principal investigator of the PROGRESSIVE AF trial, explains how cryoablation can be used as a frontline treatment for atrial fibrillation (AFib) before drugs in this AHA late-breaker. 

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Trimed Popup
Trimed Popup